EYSINS, Switzerland, Oct. 28, 2013 /CNW/ - Biosafe is pleased to report the launch of its new Smart-Max device at the ESH World Cord Blood Congress in Monaco last week.
The Smart-Max device has multiple areas of application in cell processing, including cell mixing, cooling, thawing, dilution, incubation and digestion. It is fully automated with an easy-to-use touchscreen interface and can handle bags of various sizes.
Used in conjunction with Biosafe's Sepax cell separation system, Smart-Max will bring further productivity gains to cellular product preparation.
In the cell therapy area, Sepax and Smart-Max together constitute an integrated solution, which enables complete, controlled automation of cell processing procedures, from storage to cell transplant preparation. Point of care and biotechnology applications will also benefit from this innovative technology.
Biosafe's CEO Olivier Waridel commented: "The Smart-Max demonstrates Biosafe's commitment to ongoing innovation. Smart-Max completes the already well-established Coolmix family of devices, by adding the capability of thawing cellular products. With its versatility, Smart-Max should find its place in every cell therapy facility."
Smart-Max is available now, subject to local regulatory approvals.
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao Paulo) and is present in more than 45 countries, either directly or through distributors.
SOURCE: Biosafe Group
For further information: